Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Paclitaxel and Epoetin Alfa in Advanced Ovarian Cancer
NCT00158379Phase 2Completed
- Sponsor
- NOGGO
- Start
- Jul 2003
- Primary completion
- Apr 2008
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of epoetin alfa, paclitaxel and carboplatin in ovarian cancer, sponsored by NOGGO. Primary endpoint: Progression-free Survival. Started Jul 2003; status: completed.
02
Drugs
epoetin alfapaclitaxelcarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00158379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00158379.